Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Douglas MacDonald

Showing results (71-80 of 82) with videos related to

Pageof 9
Sort By:
Molecular Cancer Therapeutics|March 8, 2017
Characterization of the Anti-PD-1 Antibody REGN2810 and Its Antitumor Activity in Human <i>PD-1</i> Knock-In MiceElena Burova, Aynur Hermann, Janelle Waite, et al.
Science Translational Medicine|June 21, 2019
A Mucin 16 bispecific T cell-engaging antibody for the treatment of ovarian cancerAlison Crawford, Lauric Haber, Marcus P Kelly, et al.
Plos One|June 24, 2014
Genetic deletion of transglutaminase 2 does not rescue the phenotypic deficits observed in R6/2 and zQ175 mouse models of Huntington's diseaseLiliana B Menalled, Andrea E Kudwa, Steve Oakeshott, et al.
Proceedings of the National Academy of Sciences of the United States of America|December 28, 2019
Kappa-on-Heavy (KoH) bodies are a distinct class of fully-human antibody-like therapeutic agents with antigen-binding propertiesLynn E Macdonald, Karoline A Meagher, Matthew C Franklin, et al.
BMJ (Clinical Research Ed.)|August 2, 2023
Mortality rates among patients successfully treated for hepatitis C in the era of interferon-free antivirals: population based cohort studyVictoria Hamill, Stanley Wong, Jennifer Benselin, et al.
Journal of Viral Hepatitis|May 27, 2024
Peer support for people living with hepatitis B virus-A foundation for treatment expansionLouise O Downs, Kenneth Kabagambe, Sarah Williams, et al.
Journal of Medicinal Chemistry|January 10, 2012
Discovery and structure-activity relationship of potent and selective covalent inhibitors of transglutaminase 2 for Huntington's diseaseMichael E Prime, Ole A Andersen, John J Barker, et al.
Scientific Reports|July 14, 2021
Generation of T-cell-redirecting bispecific antibodies with differentiated profiles of cytokine release and biodistribution by CD3 affinity tuningLauric Haber, Kara Olson, Marcus P Kelly, et al.
Science Translational Medicine|January 10, 2020
A class of costimulatory CD28-bispecific antibodies that enhance the antitumor activity of CD3-bispecific antibodiesDimitris Skokos, Janelle C Waite, Lauric Haber, et al.
Science Translational Medicine|March 26, 2025
CAR T cells based on fully human T cell receptor-mimetic antibodies exhibit potent antitumor activity in vivoRobert Salzler, David J DiLillo, Kei Saotome, et al.
Pageof 9

Showing results (71-80 of 82) with videos related to

Sort By:
Pageof 9
Molecular Cancer Therapeutics|March 8, 2017
Characterization of the Anti-PD-1 Antibody REGN2810 and Its Antitumor Activity in Human <i>PD-1</i> Knock-In MiceElena Burova, Aynur Hermann, Janelle Waite, et al.
Science Translational Medicine|June 21, 2019
A Mucin 16 bispecific T cell-engaging antibody for the treatment of ovarian cancerAlison Crawford, Lauric Haber, Marcus P Kelly, et al.
Plos One|June 24, 2014
Genetic deletion of transglutaminase 2 does not rescue the phenotypic deficits observed in R6/2 and zQ175 mouse models of Huntington's diseaseLiliana B Menalled, Andrea E Kudwa, Steve Oakeshott, et al.
Proceedings of the National Academy of Sciences of the United States of America|December 28, 2019
Kappa-on-Heavy (KoH) bodies are a distinct class of fully-human antibody-like therapeutic agents with antigen-binding propertiesLynn E Macdonald, Karoline A Meagher, Matthew C Franklin, et al.
BMJ (Clinical Research Ed.)|August 2, 2023
Mortality rates among patients successfully treated for hepatitis C in the era of interferon-free antivirals: population based cohort studyVictoria Hamill, Stanley Wong, Jennifer Benselin, et al.
Journal of Viral Hepatitis|May 27, 2024
Peer support for people living with hepatitis B virus-A foundation for treatment expansionLouise O Downs, Kenneth Kabagambe, Sarah Williams, et al.
Journal of Medicinal Chemistry|January 10, 2012
Discovery and structure-activity relationship of potent and selective covalent inhibitors of transglutaminase 2 for Huntington's diseaseMichael E Prime, Ole A Andersen, John J Barker, et al.
Scientific Reports|July 14, 2021
Generation of T-cell-redirecting bispecific antibodies with differentiated profiles of cytokine release and biodistribution by CD3 affinity tuningLauric Haber, Kara Olson, Marcus P Kelly, et al.
Science Translational Medicine|January 10, 2020
A class of costimulatory CD28-bispecific antibodies that enhance the antitumor activity of CD3-bispecific antibodiesDimitris Skokos, Janelle C Waite, Lauric Haber, et al.
Science Translational Medicine|March 26, 2025
CAR T cells based on fully human T cell receptor-mimetic antibodies exhibit potent antitumor activity in vivoRobert Salzler, David J DiLillo, Kei Saotome, et al.
Pageof 9